Frailty in VasculitisDr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at ACR22 Convergence.
Lupus, Sex and STDsDr. Kathryn Dao discusses abstract 0939 presented at the ACR22 Convergence meeting in Philadelphia, PA.Abstract 0939: Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a...
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at ACR22 Convergence.
Lupus, Sex and STDs
Dr. Kathryn Dao discusses abstract 0939 presented at the ACR22 Convergence meeting in Philadelphia, PA.
Abstract 0939: Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for Giant Cell Arteritis
Dr. Richard Conway discusses abstract 0470, being presented during Poster Session A on Saturday, November 12, 2022 at the ACR 2022 meeting.
Abstract 0470: Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
NSAIDs and CV risk in Inflammatory Arthritis
Dr. Richard Conway discusses abstract 1207, being presented during Poster Session C on Sunday, November 13, 2022 at the ACR 2022 meeting.
Abstract 1207: Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Should You Repeat the ENA Panel?
Dr. Kathryn Dao discusses abstract 0725, presented at ACR22 Convergence.
Abstract 0725: Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit
To Beta Block or Not in GCA and Large Vessel Vasculitis
Dr. Patricia Harkins discusses abstract 0477 presented on Saturday, November 12, 2022, at ACR22 Convergence.
Abstract 0477: Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting.
Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Sarilumab in Polymyalgia Rheumatica: Results from Phase 3 Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA.
Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Welcome to ACR 2022
Dr. Jack Cush, Executive Editor of RheumNow, welcomes you to Philadelphia for ACR22 Convergence!
2022 ACR/EULAR Classification Criteria for GCA
Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA.
Gender in AxSpa
Dr. Peter Nash, Philadelphia
Do Disease Activity Measures Really Capture AS in Women?
Dr. Rachel Tate interviews Dr. Sinead Mcguire about Abstract 0406, presented at ACR22 Convergence in Philadelphia, PA.
Abstract 0406: https://acrabstracts.org/abstract/are-the-basdai-basfi-capturing-the-full-impact-of-disease-activity-on-quality-of-life-in-women-with-axial-spondyloarthritis/
Dr Aurelie Najm Opoids and health care utilization in PsA and AS
Abstract 402
Poor Medication Adherence in SLE and How to Improve It
Dr. Janet Pope discusses three abstracts presented at the ACR22 Convergence meeting in Philadelphia, PA.
0343: Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
0115: Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff
0063: Implementability of a SLE Medication Adherence Intervention
Sputum anti-CCP the new diagnostic test in at-risk RA?
Dr. Aurelie Najm discusses abstract 0533 at the ACR22 Convergence meeting in Philadelphia, PA.
Abstract 0533: Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Drs Cush and Fava: Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA.
Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Social Media in Rheumatology Academia
Dr. Kathryn Dao, Dallas
Jorena Lim, third-year medical student, UTSW, Dallas
Abstract 0220
Treatment Choices and Mortality in RA ILd
Dr. Julian Segen, Philadephia
Dr. Bryant England, Philadephia
Dr Tate PsA Cycling or Switching MOAs with Dr Ogdie
Abstracts 1600 and 402.
Dr Cassy Sims The Impact of Upacitinib vs Adalimumab in Psoriatic Arthritis using RAPID
Abstract 192.
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA.
Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Dr Janet Pope Switching from a JAK Inhibiter
Abstract 0274.
Dr Yusof Effect of voclosporin in Class 5 lupus nephritis
Abstract 0355.
Best of PsA
Dr. Rachel Tate
Drs Yusof and Sexena Breakthrough COVID infection in a lupus cohort during Omicron era
Session # 12S119.
PsA Cycling or Switching MOAs
Dr. Rachel Tate interviews Dr. Alexis Ogdie at ACR22 Convergence in Philadelphia, PA.
Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract 402: Opioid Use and Healthcare Utilization in Adults with PsA and AS
Urine Proteomics in SLE with Dr. Michelle Petri
Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at ACR22 Convergence.
